Breztri Aerosphere for Asthma
The Medical Letter on Drugs and Therapeutics · 06.07.2026 · 68 (1758) · 108-109
DOI: 10.58347/tml.2026.1758c ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 06.07.2026.
Abstract (Originalsprache)
Breztri Aerosphere (AstraZeneca), a three-drug inhaler containing the inhaled corticosteroid (ICS) budesonide, the long-acting antimuscarinic agent (LAMA) glycopyrrolate, and the long-acting beta2-agonist (LABA) formoterol fumarate, has been approved by the FDA for maintenance treatment of asthma in patients ≥12 years old. It was approved in 2020 for treatment of chronic obstructive pulmonary disease (COPD). Breztri Aerosphere is the second ICS/LAMA/LABA combination to become available for treatment of asthma. Trelegy Ellipta, which contains the ICS fluticasone, the LAMA umeclidinium, and the LABA vilanterol, is FDA-approved for maintenance treatment of asthma in adults.
Schlagwörter
Stichwörter der Autor:innen
Zitieren
APA
(2026). Breztri Aerosphere for Asthma. The Medical Letter on Drugs and Therapeutics, 68(1758), 108-109. https://doi.org/10.58347/tml.2026.1758c
Vancouver
Breztri Aerosphere for Asthma. The Medical Letter on Drugs and Therapeutics. 2026;68(1758):108-109. doi:10.58347/tml.2026.1758c
BibTeX
@article{euvimed2026,
title = {Breztri Aerosphere for Asthma},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2026},
volume = {68},
number = {1758},
pages = {108--109},
doi = {10.58347/tml.2026.1758c}
}
EUVIMED